1445651-64-8

Basic information

• Product Name: benzyl tetrahydrofuran-3-carboxylate
• Synonyms: benzyl tetrahydrofuran-3-carboxylate
• CAS NO: 1445651-64-8
• Molecular Weight: 206.241
• Mol File: 1445651-64-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: benzyl tetrahydrofuran-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl tetrahydrofuran-3-carboxylate(1445651-64-8)
• EPA Substance Registry System: benzyl tetrahydrofuran-3-carboxylate(1445651-64-8)

Safety Data

• Hazardous Substances Data: 1445651-64-8(Hazardous Substances Data)

Upstream product

• 89364-31-8 3-tetrahydrofuroic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 15833-64-4 (3-methyltetrahydrofuran-3-yl)methanol 
• 89364-31-8 3-tetrahydrofuroic acid 
• 168395-26-4 (S)-tetrahydro-furan-3-carboxylic acid 
• 66838-42-4 (3R,S)-tetrahydro-furan-3-carboxylic acid 
• 130193-90-7 (S)-tetrahydro-furan-3-carboxylic acid benzyl ester 
• 130193-89-4 (R)-tetrahydro-furan-3-carboxylic acid benzyl ester 

Relevant articles and documents

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

Provided are cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor, compositions comprising said compounds, and uses of said compounds in the treatment or prevention of diseases in which M4 muscarinic acetylcholine receptors are involved, especially neurological and psychiatric disorders and diseases.

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

QUINOLINE DERIVATIVES

The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.